Guest Editor
Collection Overview
Cancer immunotherapy has emerged as one of the most exciting areas of research and cancer treatment. Different types of cancer immunotherapies share a common goal of promoting anti-tumor immune response. Direct delivery of immunostimulatory particles into the tumor microenvironment specifically aims to augment the anti-tumor immunity within the generally immunosuppressive environment. Particles containing Toll-like receptor (TLR) agonists, nucleotide-binding oligomerization domain (NOD)-like receptor agonists and cytokines are some examples. This collection of methods aims to bring together articles that share both common and innovative approaches in designing and constructing novel immunostimulatory particles and studying these immunostimulatory particles in clinical correlative studies and in vitro or in vivo model systems.
Articles
In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
0 Views
•
2025
•
1Department of Biochemistry & Molecular Biology, Arnie Charbonneau Cancer and Alberta Children's Hospital Research Institutes, University of Calgary, 2Department of Cell Biology & Anatomy, Arnie Charbonneau Cancer and Alberta Children's Hospital Research Institutes, University of Calgary, 3Department of Medicine, Oncology, and Microbiology/Immunology/Infectious Diseases, Arnie Charbonneau Cancer and Alberta Children's Hospital Research Institutes, University of Calgary, 4Department of Biochemistry & Molecular Biology and Oncology, Arnie Charbonneau Cancer and Alberta Children's Hospital Research Institutes, University of Calgary, 5Cogno-Mechatronics Engineering, Pusan National University
Abstracts
Evaluation of the antitumor activity of polyanhydride IL-1α nanoparticles
Kathleen Ross1,
Aliasger Salem2,
MM Hasibuzzaman3,
Andrean L Simons*4,
Balaji Narasimhan5
13.Department of Chemical and Biological Engineering, College of Engineering, Iowa State University, Ames, IA, 4.Nanovaccine Institute, Iowa State University, Ames, IA,,
21. Interdisciplinary Graduate Program in Human Toxicology, University of Iowa, Iowa City, IA, 4. Nanovaccine Institute, Iowa State University, Ames, IA, 5. Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, 6. Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA,
31. Interdisciplinary Graduate Program in Human Toxicology, University of Iowa, Iowa City, IA, 2. Department of Pathology, University of Iowa, Iowa City, IA.,
41. Interdisciplinary Graduate Program in Human Toxicology, University of Iowa, Iowa City, IA, 2. Department of Pathology, University of Iowa, Iowa City, IA, 4. Nanovaccine Institute, Iowa State University, Ames, IA, 5. Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, 6. Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, 7. Department of Oral Pathology, Radiology and Medicine, College of Dentistry, University of Iowa, Iowa City, IA.,
53. Department of Chemical and Biological Engineering, College of Engineering, Iowa State University, Ames, IA, 4. Nanovaccine Institute, Iowa State University, Ames, IA